Novavax Now Covered by Analysts at FBR & Co. (NVAX)
Equities research analysts at FBR & Co. assumed coverage on shares of Novavax (NASDAQ:NVAX) in a research note issued to investors on Wednesday, Analyst Ratings News reports. The firm set an “outperform” rating on the stock.
Novavax (NASDAQ:NVAX) traded up 7.96% during mid-day trading on Wednesday, hitting $3.12. 4,247,433 shares of the company’s stock traded hands. Novavax has a one year low of $1.52 and a one year high of $3.50. The stock’s 50-day moving average is $2.85 and its 200-day moving average is $2.36. The company’s market cap is $476.3 million.
Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, August 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.02. The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $4.45 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The company’s revenue for the quarter was down 50.7% on a year-over-year basis. Analysts expect that Novavax will post $-0.26 EPS for the current fiscal year.
NVAX has been the subject of a number of other recent research reports. Analysts at FBR Capital Markets initiated coverage on shares of Novavax in a research note to investors on Wednesday. They set an “outperform” rating and a $11.00 price target on the stock. Separately, analysts at MLV Capital raised their price target on shares of Novavax from $8.50 to $9.50 in a research note to investors on Wednesday, September 25th. They now have a “buy” rating on the stock. Finally, analysts at Lazard Capital Markets raised their price target on shares of Novavax from $4.00 to $11.00 in a research note to investors on Thursday, August 15th. They now have a “positive” rating on the stock. Eight equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $8.88.
Novavax, Inc (NASDAQ:NVAX), is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.